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Multilocus variable-number tandem-repeat analysis 
(MLVA) of 316 Bordetella pertussis isolates collected over 
40 years from Australia and 3 other continents identiﬁ  ed 66 
MLVA types (MTs), including 6 predominant MTs. Typing of 
genes encoding acellular vaccine antigens showed changes 
that may be vaccine driven in 2 MTs prevalent in Australia.
D
espite longstanding vaccination programs, pertussis 
remains endemic to many industrialized countries, 
including Australia, Canada, Italy, Japan, the Netherlands, 
Switzerland, and the United States, all of which have re-
ported recent increases in incidence (1). Although pertussis 
is classically a disease of infants and children, this increase 
has been mainly among adults and adolescents (2,3). Fac-
tors contributing to pertussis resurgence remain unclear, 
but possible causes are waning immunity, suboptimal vac-
cine coverage, improved surveillance and diagnosis, the 
switch from whole cell vaccine (WCV) to acellular vaccine 
(ACV), and adaptation of circulating Bordetella pertussis 
strains (4–9). To determine the global epidemiology of per-
tussis, we analyzed an international collection of B. pertus-
sis isolates collected mainly over the past 40 years.
The Study
We used 8 variable-number tandem-repeats, including 
6 from Schouls et al. (10), to develop a multiplex PCR mul-
tilocus variable-number tandem-repeats analysis (MLVA) 
assay (Table 1; online Technical Appendix, www.cdc.gov/
EID/content/16/2/297-Techapp.pdf) and used it to charac-
terize 316 B. pertussis isolates from 12 countries on 4 conti-
nents, including 208 isolates from Australia and 87 isolates 
representative of common pulsed ﬁ  eld gel electrophoresis 
types from Canada, Japan, Finland, and the United States 
(complete list available from authors). The Simpson index 
of diversity (D) ranged from 0.02 to 0.73 per locus with a 
combined D of 0.911 (Table 2). The isolates were resolved 
into 66 MLVA types (MTs) (complete list available from 
authors). Thirty-ﬁ  ve MTs were represented by single iso-
lates, including 15 of 208 isolates from Australia and 10 of 
49 isolates from Japan. Thirty-seven MTs were previously 
found in Europe (10,11) and 27 were novel. Fourteen MTs 
were found in >2 countries or regions.
The 208 isolates from Australia were grouped into 37 
MTs, of which the 4 most prevalent represented 65.4% of 
the isolates: MT27, 13.5%, including 1 isolate from 1973 
and the others from the 1990s to 2008; MT29, 21.6%, 
observed since 1972; MT70, 21.2%, 1996–2005, mostly 
since ACV introduction in 1997; and MT64, 9.1%, during 
1989–2002. Prevalence trends of the 4 most common MTs 
were analyzed for 3 periods determined by vaccine type(s) 
in use: WCV (prior to 1997), the transition period of both 
WCV and ACV (1997–1999), and ACV only (2000 on-
ward) (Figure 1). MT64 prevalence was steady over time. 
MT29 decreased while MT27 and MT70 increased. Trends 
in Australia for MT27 and MT29 were similar to those ob-
served in the United Kingdom (11) and the Netherlands 
(10). D values were 0.86, 0.83, and 0.83 for WCV, transi-
tion, and ACV periods, respectively. This slight decrease 
in genetic diversity might indicate expansion of clones that 
are better adapted to ACV-induced immunity.
We typed 5 genes, the products of which are used in 
ACVs (prn, ptxA, ﬁ  m2, ﬁ  m3, and fhaB), using the method of 
Chan et al. (12) to assess the effect of the switch from WCV 
to ACV on prevalence of the 4 predominant MTs (MT27, 
MT29, MT64, and MT70) in Australia. Isolates from these 
MTs have the same ptxA1 and fhaB1 alleles but vary in the 
other 3 genes investigated (complete list available from 
authors). The predominant ACV used in Australia is from 
GlaxoSmithKline (GSK) (Research Triangle Park, NC, 
USA), which contains pertussis toxoid, ﬁ  lamentous hemag-
glutinin, and pertactin but no ﬁ  mbriae (FIMs). The strain 
used for GSK ACV contains the alleles prn1, ptxA2, and 
fhaB1 (10,13). However, ACV from Sanoﬁ  -Aventis (Pas-
teur, Lyon, France), which contains FIM2+3 in addition to 
pertussis toxoid, pertactin, and ﬁ  lamentous hemagglutinin 
with unknown allele types, is also licensed in Australia, 
complicating interpretation of variation in ﬁ  m genes. On the 
basis of their frequencies and late appearance, ﬁ  m2-2 and 
ﬁ  m3-B are not likely to be the vaccine alleles. A signiﬁ  cant 
increase (p<0.005) of prn2 (36% vs. 3%), ﬁ  m2-2 (34% vs. 
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This increase of allelic frequency is better reﬂ  ected in 
changes in antigenic proﬁ  les. MT27 has 3 proﬁ  les (prn1, 
ﬁ  m2-1,  ﬁ  m3-A; prn2, ﬁ  m2-1,  ﬁ  m3-A;  and prn2, ﬁ  m2-1, 
ﬁ  m3-B). The ﬁ  rst proﬁ  le was seen once in the WCV pe-
riod, whereas the other 2 ﬁ  rst appeared in the WCV/ACV 
transition period and increased in frequency in the ACV 
period; the third proﬁ  le, which differed by 2 alleles from 
the ﬁ  rst, was more frequent. The appearance of prn2 in the 
second proﬁ  le and additional change from ﬁ  m3-A to ﬁ  m3-B 
in the third represent increases in prevalence of alleles ab-
sent from ACV. MT29 also has 3 proﬁ  les ([prn1, prn2, 
or prn3], ﬁ  m2-1, ﬁ  m3-A), which differ in prn only. Most 
MT29 isolates carry prn3, and the proﬁ  le is prevalent in 
both WCV and ACV periods, with no obvious increase in 
non-ACV alleles.
MT70 and MT64 both have uniform allelic proﬁ  les 
(prn1,  ﬁ  m2-2,  ﬁ  m3-A and prn1,  ﬁ  m2-1,  ﬁ  m3-A, respec-
tively). However, MT70 (with ﬁ  m2-2, not likely to be in 
ACV) increased signiﬁ  cantly over the study period while 
MT64 with all alleles likely to be in ACV remained steady. 
Overall, the frequency of MT27 and MT70, with non-ACV 
alleles, increased signiﬁ  cantly (p<0.0001) and correlated 
with the introduction of ACV, suggesting that antigenic 
changes could be driven by selection pressure.
The 2 MTs predominant in Australia were also preva-
lent in other countries and possibly have a global distribu-
tion. MT27 (18% of isolates) was found in 8 countries and 
MT29 (17% isolates) in 5. However, absence of an MT in 
a country might result from the small samples used. MT27 
and MT29 were the most common types in the Netherlands 
(10) and the United Kingdom (11). MT10, MT64, MT70, 
MT84, and MT186 were also relatively common. MT10 
and MT186 were found predominantly in Japan, although 
each had been found elsewhere, in China (1957) and Hong 
Kong (2002), respectively. MT64 was predominantly from 
Australia with 1 isolate from Japan, and MT70 was only 
found in Australia. However, all of these frequent MTs 
(except MT186) have been observed before. MT10 was 
frequent in the United Kingdom in the prepertussis vaccine 
era, while MT70 was common during 1998–2001 (11).
Nine isolates, including Tohama I, indentiﬁ  ed in sam-
ples of pertussis strains collected during the 1920s–1950s 
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Table 1. Primers used in study of Bordetella pertussis clones Identified by multilocus variable-number tandem-repeat analysis 
Primer name  Sequence, 5ƍ ĺ 3ƍ 
Genome 
coordinates*  Mix 
Concentration,† 
PM Reference 
BP-VNTR1-DF VIC-CCTGGCGGCGGGAGACGTGGTGGTG 2194507 1 (10) 
BP-VNTR1-DR AAAATTGCGGCATGTGGGCTGACTCTGA 2194862 1 
0.13 
(10) 
BP-VNTR2-BF   VIC-CGCGCCGCCTACGACCGCTATGG 2647550 2  (10) 
BP-VNTR2-BR CCCGCGCCGAAGATCTCGCCAAAGATAT 2647412 2 
0.08  
(10) 
BP-VNTR3-BF   FAM-GCCTCGGCGAAATTGCTGAAC 2591464 2  (10) 
BP-VNTR3-BR GCGGGCGAGGAAACGCCCGAGACC 2591350 2 
0.23  
(10) 
BP-VNTR4-CF   NED-CGTGCCCTGCGCCTGGACCTG 185211 2  (10) 
BP-VNTR4-BR GCCGCTGCTCGACGCCAGGGACAA 185000 2 
0.08  
(10) 
BP-VNTR5-BF   PET-GAAGCCGGCCCACCCGAGCTCCAGGCTCTT 1005290 1  (10) 
BP-VNTR5-BR TGCCGGGTTTCGGCATCTCGATGGGATACG 1005177 1 
0.06  
(10) 
BP-VNTR6-EF   FAM-CCAACGGCGGTCTGCTGGGTGGTC 2099525 1 (10) 
BP-VNTR6-FR CGCCGCCCGCTGCGCCGCTACC 2099315 1 
0.06  
(10) 
VNTR7F2   PET-ATCAGGAAACCCACCACCACGCCGG 124402  2  This  study 
VNTR7R2 GTCACCAGCCCGCAGTACTGGCG 124585  2 
0.08  
This study 
VNTR8F2   NED-TGGGTGTCTCCGTGATAGTGAGCACTTACAC 444776  1  This  study 
VNTR8R2 CTGGCGCAAAAACAGTAAGCCCGCACG 444981  1 
0.19 
This study 
*Based on genome sequence position of the Tohama I strain; VNTR, variable-number tandem-repeat. 
†Concentrations listed are for forward and reverse primers separately. 
Table 2. Diversity of variable-number tandem-repeat analysis loci Bordetella pertussis isolates* 
Global (this study)  Australia (this study)  The Netherlands (10)
Locus No. repeats  No. alleles  D No. alleles  D No. alleles  D
VNTR1 2–12 6 0.58 4 0.63 7 0.26
VNTR2 2–5 4 0.02 2 0.01 3 N/A
VNTR3a 2–8 4 0.40 4 0.43 10 0.18
VNTR3b 0–10 5 0.21 5 0.21 4 0.15
VNTR4 2–9 7 0.34 5 0.24 8 0.21
VNTR5 3–9 6 0.20 4 0.19 7 0.18
VNTR6 2–11 8 0.72 5 0.70 8 0.60
VNTR7 3–4 2 0.01 1 0.00 NA NA
VNTR8 2–4 3 0.16 2 0.03 NA NA
*D, Simpson index of diversity; VNTR, variable-number tandem-repeat; NA, not applicable. B. pertussis Clones 
from 5 countries (China, France, Japan, United Kingdom, 
and United States) were distributed among 7 MTs: MT10, 
MT12, MT75, MT83, MT127, MT205, and MT206, 2 of 
which were also represented among recent strains: MT10, 6 
isolates from Japan 1989–2007; and MT75, 1 isolate from 
France in 1993. The remaining 5 MTs were either unique 
or shared only among the 9 early isolates.
MLVA data were used to construct a minimum span-
ning tree (MST) (Figure 2). The 66 MTs were grouped 
into 2 clonal complexes and 9 singletons. Most MTs (54 
of 66) belong to 1 clonal complex and 3 (MT186, MT187, 
and MT194) belong to another. Relationships between 
singletons with multiple allelic differences are not robust 
because they can be connected to other nodes equally. 
Thus, the MST cannot be rooted to infer the direction of 
change. Two internationally predominant MTs (27 and 
29) are closely related with 1 allele difference. MT10, 
prevalent in Japan, is also closely related to MT29, with 
1 allele difference. MT29, ﬁ  rst isolated in the prevaccine 
era in the United Kingdom (11), has the highest number 
of SLVs and was found over 4 continents, which sug-
gests that it arose early. Because MT10 and MT27 have a 
high frequency of SLVs, both likely emerged quite early. 
MT10 was isolated as early as 1957 in China and MT27 
in 1950 in the Netherlands (10). Two high-frequency MTs 
(MT64 and MT70) were found in Australia only recently, 
with few SLVs, and may have contributed to the resur-
gence of pertussis in Australia.
Conclusions
Analysis of 208 isolates from Australia and repre-
sentative isolates of common pulsed-ﬁ  eld gel electropho-
resis types from Canada, Japan, Finland, and the United 
States identiﬁ  ed 6 predominant MTs (clones). Two (MT27 
and MT29) were distributed worldwide, while 4 (MT10, 
MT64, MT70 and MT186) predominated in speciﬁ  c coun-
tries. Several MTs have persisted over long periods, includ-
ing 3 that have circulated for at least half a century. Typing 
of genes encoding ACV antigens showed that use of ACV 
may have driven antigenic changes of 2 MTs now predomi-
nant in Australia.
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Figure 1. Temporal trends of predominant multilocus variable-
number tandem-repeat analysis (MLVA) types in Australia. Isolates 
of 4 major MLVA types (MT70, MT27, MT29, and MT64) obtained 
in Australia were divided into 3 periods: whole cell vaccine (WCV) 
(before 1997), transition from WCV to acellular vaccine (ACV) 
(1997–1999) and ACV (2000 onward). 
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Figure 2. Minimum spanning tree (MST) of multilocus variable-
number tandem-repeat analysis (MLVA types for global Bordetella 
pertussis isolates. The MST produced in Bionumerics (Applied 
Maths, Kortrijk, Belgium) used categorical coefﬁ   cient and the 
eBURST priority rule of the highest number of single-locus changes 
for the clustering. Each circle represents an MLVA type with the 
type number in the circle. Thick lines, types differing by a single 
MLVA locus; thin lines, double-locus variants; dotted lines, 2 types 
differing by >2 MLVA loci. The size of the circle reﬂ  ects the number 
of isolates with a given MLVA type. The color codes for country of 
origin are shown, and pie charts within a circle are used to indicate 
the proportion of isolates.Mr Kurniawan is a PhD student in medical microbiology at 
the University of New South Wales, Sydney, Australia. His re-
search interests include molecular epidemiology and evolution of 
B. pertussis.
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